A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) AS ADJUVANT THERAPY IN PATIENTS WITH RENAL CELL CARCINOMA AT HIGH RISK OF DEVELOPING METASTASIS FOLLOWING NEPHRECTOMY
The purpose of this study is to compare the safety and effects of atezolizumab (the study drug) with a placebo on people and their risk of RCC.
Renal Cell Carcinoma
RCC with a recent nephrectomy or metastasectomy. Further tests, procedures, and a review of your medical history will be done to confirm eligibility.
18 - 120
Healthy Volunteers Needed
Duration of Participation
Treatment will last for up to 1 year. Continued follow up will last for as long as your cancer has not returned.
Knight Clinical Trials
F. Hoffmann-La Roche Ltd